Sweden’s Elekta Q4 operating profit beats expectations at SEK 902 mln

Elekta’s print looks less like a clean demand recovery and more like a margin/operations reset story that is now close to fully reflected in the base. The key tell is that profitability improved despite weak order intake, which usually means the benefit is coming from cost actions, mix, and accounting normalization rather than a sustainable acceleration in end demand. That matters because in med-tech capital equipment, a “better EBIT on worse orders” setup tends to lag in valuation until orders inflect; until then, the market often treats the improvement as quality-adjusted but not yet durable.

The second-order issue is pipeline timing. A sharp order miss in a business with long sales cycles can create a false sense of stability in the next 1-2 quarters if hospitals delay, then catch up; alternatively, it can foreshadow a softer FY27 if budget cycles have slipped. The fact that FX aided/ hurt lines in opposite directions also means consensus may be overestimating operating leverage: if currencies normalize, headline growth can improve while gross margin gives some back, limiting multiple expansion.

The balance-sheet and cash-flow progress likely matter more than the quarter’s P&L. Net debt down and stronger cash conversion reduce near-term financing risk, which can support the dividend and lower equity downside, but they do not by themselves solve the core issue: whether the installed base can generate enough replacement demand to sustain mid-single-digit constant-currency growth. The market is probably underpricing how much of the near-term upside is already embedded in the cost-reset narrative, while underappreciating the risk that FY27 guidance proves conservative if order weakness persists.

Contrarian read: this is not a turnaround to chase aggressively after a single quarter; it is a “show me the orders” setup. The most interesting window is likely 1-2 quarters out, when cost savings are already in the run-rate but revenue visibility either validates or breaks the thesis. If orders stabilize, the operating leverage could re-rate sharply; if not, the stock can drift lower even as reported margins remain respectable.